Overview

Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel

Status:
Withdrawn

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

Although there have been advances in the treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC), all patients eventually develop resistance to available therapy. Docetaxel is the accepted first-line agent followed by cabazitaxel in the post-docetaxel phase. In this study the investigators propose to evaluate BKM120, a PI3K inhibitor, with cabazitaxel in the treatment of patients with advanced prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

SCRI Development Innovations, LLC

Collaborator:

Novartis

Treatments:

Docetaxel